Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients

Burns Clinical Trial

Official title:

Comparison of the Efficacy and Safety for Different Regimen of Venous Thromboembolism Pharmacoprophylaxis Among Severely Burn Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05237726
• Other study ID #: RC18-400-R
• Status: Completed
• Phase: N/A
• Start date: April 5, 2020
• Est. completion date: February 28, 2022

Study information

• Verified date: December 2022
• Source: King Abdullah International Medical Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to assess the feasibility and safety of VTE prophylaxis for 3 modality regimens (Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours) in adult patients (≥18 y/o) with severely burn injuries (BSA≥20%) by measuring the bleeding incidence and VTE events.

Description:

This is a pilot , randomized control trial-Open label, prospective trial in tertiary academic hospitals for patient admitted to burn ICU for at least 24 hours of injury or transferred from other hospital(s) within 7 days of injury. Each patient admitted meets the inclusion criteria will be randomize by block randomization to either receive heparin 5000 units S.C. TID, enoxaparin 40 mg S.C. OD, or Enoxaparin 30 mg S.C. BID. VTE prophylaxis should be started within 36 hours of injury, if the patient is transferred from another facility, VTE prophylaxis should be started immediately unless contraindicated. All patients should undergo diagnostic ultrasound at baseline ( before starting the prophylaxis) to assess any presence of DVT and as clinically indicated for clinical suspicion for VTE thereafter until discharge, an urgent spiral CTA chest will be requested on clinical suspicion for PE. Anti Xa factor will be monitored at day 3, and weekly thereafter until discharge unless there is active bleeding or high clinical suspicion for bleeding. Will follow-up patient until discharge from ICU, developed VTE requiring treatment (switch to treatment dose), developed HIT or death.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 28, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Burn ICU admitted adult patients, age = 18 years old.

• Body Mass Index of 18.5 to < 40 kg/m2.

• TBSA of 20% or more.

Exclusion Criteria:

• VTE history.

• Death within 24 hours of injury.

• Burn injuries combined with trauma requiring withholding pharmacoprophylaxis more than 48 hours.

• Coagulopathy (INR > 1.7, PTT> 2 times upper normal limit, platelet < 50k mm3)

• Patient with positive baseline US for VTE.

• Heparin induced thrombocytopenia (HIT).

• Active bleeding.

• Patients with CrCl of 30 ml/min or less.

• Patients using anticoagulation treatment dose for other indications.

Related Conditions & MeSH terms

• Burns

Intervention

Drug:
• Enoxaparin 40 mg q24 hours
Severely burn injuries (BSA=20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
• Enoxaparin 30 mg q12 hours
Severely burn injuries (BSA=20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
• Unfractionated heparin 5000 U q8 hours
Severely burn injuries (BSA=20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

Locations

Country	Name	City	State
Saudi Arabia	King Abdulaziz Medical City	Riyadh

Sponsors (1)

Lead Sponsor	Collaborator
King Abdullah International Medical Research Center

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of bleeding events (major and minor)	Daily assessment of major and minor Bleeding. Bleeding will classified into major and minor bleeding. Major bleeding defined as clinically overt bleeding associated with a fall =Hb 20g/L, transfusion of =2U PRBC or whole blood, retroperitoneal or intracranial bleeding or requiring urgent medical intervention. Minor bleeding defined as those not fulfilling the criteria of major or clinically significant bleeding.	Through study completion, an average of 2 years
Primary	Adverse effects in surgical outcomes (i.e. Graft loss, donor site morbidity, requirement of hemostatic intervention).	Daily assessment of donor site and graft site bleeding/failure.; Graft site bleeding defined as bleeding at skin graft recipient site that requires premature wound exploration ( before 3 days postoperatively), bed side or operating room intervention to stop bleeding ( stitching, hemostatic agent or cauterization) with or without blood transfusion.; Donor site bleeding/hematoma is any bleeding leading to a drop in hemoglobin > 2 grams, hemodynamic instability or bleeding requiring urgent transfusion.; Graft failure due to hematoma that require re-grafting or more than 50% of the graft site.; Enoxaparin should be held 12 hours and unfractionated heparin 3-4 hours before percutaneous tracheostomy OR epidural catheter if indicated.	Through study completion, an average of 2 years
Primary	Recruitment and consent rates	To assess the recruitment and consent rate to evaluate trial feasibility	Through study completion, an average of 2 years
Secondary	Target anti Xa factor for enoxaparin or unfractionated heparin in severely burn patients.	Anti-Xa: Blood samples for Anti-Xa were obtained day 3 after patient is admitted to ICU (Plasma sample will be collected in blue tube "no citrate" ~ 5 mL/Test), then Anti-Xa obtained weekly thereafter until discharge. Anti-Xa obtained immediately 4 hours after administration of Enoxaparin and 3 hours after administration of unfractionated Heparin	Through study completion, an average of 2 years
Secondary	Incidence of Heparin induced thrombocytopenia (HIT).		Through study completion, an average of 2 years
Secondary	Number of days that patients stay in hospital	The length of an inpatient episode of care, calculated from the day of admission in hospital to day of discharge/death	Through study completion, an average of 2 years
Secondary	Number of patients died within intensive care unit stay	The number of deaths of patients admitted to the intensive care unit (ICU), divided by the number of patient discharges from the ICU (including deaths and transfers).	Through study completion, an average of 2 years
Secondary	Incidence of VTE events (Symptomatic)	All patients participating in the study should undergo bilateral lower extremity duplex scan to rule out DVT at baseline before starting VTE prophylaxis and as clinically indicated for clinical suspicion for VTE thereafter until discharge from ICU, developing VTE incident or death.; Urgent spiral CTA chest will be requested on clinical suspicion for PE.	Through study completion, an average of 2 years